Next-Generation Clinical Mass Spectrometry Platform

下一代临床质谱平台

• 批准号: 8739666
• 负责人: MARVIN L VESTAL
• 金额: $ 38.5万
• 依托单位: VIRGIN INSTRUMENTS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8739666
• 关键词: Address; Antibodies; Arizona; Basic Science; Biological Assay; Biological Markers; Biomedical Research; Businesses; Characteristics; Clinical; Clinical Endocrinology; Clinical Research; Computer software; Consumption; Data; Detection; Disease; Electrospray Ionization; Enzymes; Feedback; Future; Goals; Health Status; Heterogeneity; Human; Immunoassay; Individual; Institutes; Intellectual Property; Investigation; Knowledge; Label; Laboratories; Lead; Ligands; MALDI-TOF Mass Spectrometry; Marketing; Marshal; Mass Spectrum Analysis; Medical center; Medicine; Molecular; Monitor; Output; Peptides; Performance; Phase; Population; Production; Protein Binding; Proteins; Proteomics; Protocols documentation; Public Health; Radioisotopes; Reporter; Reproducibility; Research; Research Personnel; Resources; Sampling; Solutions; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Structure; System; Techniques; Technology; Testing; To specify; Translating; Translations; Universities; Validation; Variant; Washington; Work; assay development; base; biological research; clinical application; clinical research site; clinically relevant; clinically significant; cost; design; evaluation/testing; fluorophore; innovative technologies; instrument; interest; meetings; member; next generation; novel; pancreatic secretory trypsin inhibitor I; programs; prototype; research clinical testing; stem; success; tool

DESCRIPTION (provided by applicant): Mass spectrometry is now established as an essential tool in the biological research laboratory and is widely used for characterizing clinicaly significant peptides and proteins. However, more than twenty years after the advent of the enabling approaches of matrix-assisted laser desorption/ionization (MALDI) and electrospray ionization, there has been only marginal success in the implementation of mass spectrometry in routine clinical determination of proteins. In large part, this may be attributed to the fact that t present there is no concerted enterprise that systematically tailors and produces devoted analytical platforms and matched standardized assays to meet the specifications and needs of clinical practitioners. In this project we respond to this problem by assembling pioneers in the design, production and application of MALDI-time-of-flight mass spectrometry and mass spectrometric immunoassay: two technologies that will be combined to form a Next- Generation Clinical Mass Spectrometry Platform. These team members are joined by experts in the fields of Clinical Endocrinology and Population Proteomics, whose guidance is essential in defining platform specifications and lead assays for routine clinical application, as well as for producing the data that underpin an understanding of the importance of protein diversity in the human population. In this project a cross-disciplinary Industrial and Academic team will design and build a new, dedicated high-performance mass spectrometry platform to clinical specifications, and translate it and accompanying standardized assays into tools that can be exploited in clinical research. The small business members of this team possess unique expertise, intellectual property, and facilities not only to develop the new mass spectrometry platform and assays but also to marshall the resources needed to make the results of the project commercially available in phase III. Completion of this Program will impact a Scientific Knowledge Gap (of protein microheterogeneity in human populations) aligned with numerous current and future Significant Research Opportunities in Basic and Clinical Research. Also a scalable Translational Mechanism will be created that expands beyond the initial scope of this Program and deeper into long-term clinical markets by adding more assays towards known clinically significant proteins, as well as other new candidate biomarkers. Consequently, we anticipate the increased use of our Next-Generation Clinical Mass Spectrometry Platform in clinical scenarios where standardized technologies are routinely applied toward known markers to help define pathobiology's underlying disease, the clinical status of individuals with disease, and as part of advanced workflows toward novel biomarkers stemming from numerous protein-based discovery efforts currently ongoing worldwide.

描述（由申请人提供）：质谱现在是生物学研究实验室中必不可少的工具，被广泛用于表征临床上的重要肽和蛋白质。然而，在基质辅助激光解吸/电离（MALDI）和电喷雾电离的能力实现方法的出现之后，在常规的蛋白质常规临床确定中实施质谱方面仅取得了很大的成功。在很大程度上，这可能归因于以下事实：T存在系统地量身定制和生成专门的分析平台和匹配的标准化测定法以满足临床从业者的规格和需求。在这个项目中，我们通过在MALDI-Pime-of Pimple质谱和质谱免疫测定法的设计，生产和应用中组装开拓者来应对这一问题：两种将结合起来形成下一代临床质谱平台的技术。这些团队成员与临床内分泌学和人群蛋白质组学领域的专家一起加入，他们的指导对于定义平台规格和常规临床应用的铅分析至关重要，以及生成基于了解蛋白质多样性重要性的数据在人口中。 在这个项目中，跨学科的工业和学术团队将设计并建立一个新的专用高性能质谱平台，并将其转换为临床研究中可以利用的工具。该团队的小型企业成员拥有独特的专业知识，知识产权和设施，不仅是为了开发新的质谱平台和测定法，而且还可以使在第三阶段中商业上获得该项目的结果所需的资源。该计划的完成将影响科学知识差距（人群中蛋白质微观的差异）与基础和临床研究中当前和未来的重要研究机会保持一致。还将创建一种可扩展的翻译机制，该机制扩展到该计划的初始范围之外，并通过为已知的临床意义蛋白以及其他新的候选生物标志物添加更多测定法，从而更深入到长期的临床市场。因此，我们预计在临床情况下，我们预计下一代临床质谱平台的使用会增加，在临床情况下，标准化技术通常应用于已知的标记，以帮助定义病理生物学的潜在疾病，患有疾病的个体的临床状况，并且作为高级工作流程的一部分。新颖的生物标志物是源于目前在全球范围内正在进行的许多基于蛋白质的发现工作。